1  be developed to block functions mediated by IL-8RB.

2  and NAP-2 distinct from those on IL-8RA and IL-8RB; 2) IL-8, GRO alpha and NAP-2 bound to overlappin

3 mapped differentially to multiple domains on IL-8RB; 3) high affinity radioligand binding and high ag

4 Herein we describe interleukin-8 receptor B (IL-8RB, also termed CXCR2) immunoreactivity in the centr

5 egion from TMD4 to the end of the e2 loop of IL-8RB, and functioned independently of each other.

6 an interleukin-8 receptors A (IL-8RA) and B (IL-8RB) are seven-transmembrane domain (TMD) neutrophil

7 al interleuin-8 (IL-8) receptors (IL-8RA and IL-8RB: CXCR1 and CXCR2, respectively) have been describ

8 These results demonstrate for the first time IL-8RB immunoreactivity in the central nervous system an

9                      In Alzheimer's disease, IL-8RB immunoreactivity is also present in some swollen

10                                       Strong IL-8RB immunoreactivity is present in both Alzheimer's d

11                                              IL-8RB is selective for IL-8, growth-related oncogene al

12                       The strong presence of IL-8RB on neurons and the potential of glial cells to pr

13 ocal microscopic analysis reveals that these IL-8RB-positive neurites in plaques are neurofilament po

14                            In general, these IL-8RB-positive neurities do not co-localize with PHF-1

15 ns of sequence divergence between IL-8RA and IL-8RB (the N-terminal segment before TMD1, the region f

16 ates the receptors CXCR1 (IL-8RA) and CXCR2 (IL-8RB) to induce chemotaxis in leukocytes, but only CXC

17  CXCR1 (formally IL-8RA) and CXCR2 (formally IL-8RB), using blocking monoclonal antibodies (mAbs) to

18  coupled receptors CXCR1 (IL-8RA) and CXCR2 (IL-8RB), while GROalpha, GRObeta, GROgamma, and ENA-78 b